Neotigason (Acitretin)

Acitretin, the active ingredient in Neotigason, is a retinoid presented as an oral tablet for oral use. It is indicated for the treatment of severe psoriasis, psoriatic erythroderma, and other keratinization disorders in adult patients who have not responded adequately to topical therapies.

GNH USA supplies Neotigason as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies, and clinics worldwide with a focus on quality assurance, regulatory compliance and reliable logistics support for global distribution across multiple regions.

Neotigason (acitretin) is used in the management of disorders characterized by abnormal keratinocyte proliferation and differentiation.

Severe psoriasis: reduces scaling, erythema, and plaque thickness, leading to marked improvement in skin appearance and patient quality of life. Psoriatic erythroderma: helps achieve disease control and diminishes extensive erythema and desquamation across large body surface areas. Other keratinization disorders: normalizes epidermal differentiation and reduces hyperkeratosis, providing clinical benefit in conditions such as pityriasis rubra pilaris.

Adverse reactions may occur with acitretin therapy and are categorized by frequency.

Common Side Effects: - Dry skin and mucous membranes, including cheilitis. - Elevated liver enzymes (transaminases). - Hyperlipidemia, particularly increased triglycerides. - Hair thinning or loss. - Headache or mild dizziness. - Gastrointestinal discomfort such as nausea.

Serious or Rare Side Effects: - Severe hepatotoxicity or liver failure. - Acute pancreatitis, especially with marked hypertriglyceridemia. - Depression, suicidal ideation, or other psychiatric disturbances. - Teratogenic effects leading to severe fetal malformations. - Bone toxicity, including premature epiphyseal closure. - Severe hypersensitivity reactions such as Stevens‑Johnson syndrome.

Before initiating therapy, clinicians should evaluate several safety parameters.

Pregnancy: Contraindicated in pregnancy (Category X) due to high teratogenic risk; effective contraception is required. Women of childbearing potential: Must use reliable contraception for at least 3 years after discontinuation. Liver function: Obtain baseline liver enzymes and monitor periodically during treatment. Lipid profile: Check fasting triglycerides and cholesterol before starting and at regular intervals. Bone health: Assess for skeletal disorders; avoid use in patients with uncontrolled hypercalcemia. Store at ambient temperature: Keep below 25 °C, retain in original packaging, and protect from moisture and direct sunlight.

Acitretin may interact with several medicines, requiring dose adjustments or avoidance.

Major Interactions (Avoid): - Tetracyclines: Increased risk of intracranial hypertension. - Vitamin A supplements: Additive retinoid toxicity. - Methotrexate: Enhanced hepatotoxic potential.

Moderate Interactions (Monitor Closely): - Combined oral contraceptives: Reduced contraceptive efficacy. - Lipid‑lowering agents (e.g., statins): Potential alteration of lipid levels. - Antifungal agents such as ketoconazole: May raise acitretin plasma concentrations.